Clinical Trial Update: Clinical Trial Comparing TaurolockTMHep100 (Taurolidine 1.35%) and 0.9% Saline As Prevention of Recurrent Catheter-related Bloodstream Infections [NA]

View source ↗

Summary

A completed clinical trial comparing Taurolock Hep100 (taurolidine 1.35%) to 0.9% saline for preventing recurrent catheter-related bloodstream infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Catheter-related Bloodstream Infection
• Intestinal Failure

Drugs mentioned

• Taurolock Hep100 (taurolidine)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Catheter Related Blood Stream Infections, Intestinal Failure | NA | Status: COMPLETED